OpenAI CEO Sam Altman is ramping up his investment in Retro Biosciences, a San Francisco-based biotech company that aims to extend the healthy human lifespan by an additional 10 years. As reported by the Financial Times, the company is now raising US$1 billion in a Series A funding round, which Altman is supporting.

https://www.techedt.com/retro-biosciences-backed-by-sam-altman-aims-for-us1-billion-to-revolutionise-ageing